News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Rho Principal Investigator Accepts Prestigious Editorial Board Appointment



3/22/2011 12:20:55 PM

Chapel Hill, NC – – Dr. David Iklé has been invited to join the American Journal of Transplantation (AJT) Editorial Board as a Statistical Editor. Dr. Iklé's invitation was based on his contributions to transplantation literature in general, contributions to AJT in particular, the thoughtful and attentive reviews he has conducted of previous manuscripts, and his reputation as a thought leader in the field of transplantation, specifically as it applies to statistical methodologies. Statistical editor is a new category of editor for AJT. The category has been added to facilitate proper management of manuscripts whose results rely on more complex statistical methods. Dr. Iklé will be one of three statistical editors.

Dr. Iklé is the principal investigator (PI) for the statistical and clinical coordinating center (SACCC) for both the Clinical Trials in Organ Transplantation (CTOT) and Clinical Trials in Organ Transplantation in Children (CTOT-C) programs. The CTOT program is sponsored by the National Institute of Allergy and Infectious Disease (NIAID) with co-funding from the National Heart, Lung, and Blood Institute (NHLBI), and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The CTOT-C program is sponsored by NIAID with co-sponsoring from NHLBI. More information about Dr. Iklé's work and the CTOT and CTOT-C programs is available at www.rhoworld.com/rho/federal-research.

Rho, a privately-held, contract research organization (CRO) located in Chapel Hill, NC, provides a full range of services across the entire drug development process. For more than 25 years, Rho has been a trusted partner to some of the industry’s leading pharmaceutical, biotechnology, and medical device companies as well as academic and government organizations. Our commitment to excellence, our innovative technologies, and our therapeutic expertise accelerate time to market, maximize returns on investment, and lead to an exceptional customer experience.


Read at BioSpace.com


comments powered by Disqus
Rho
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES